R. Hoffmann

发表

SR 46559 A and related aminopyridazines are potent muscarinic agonists with no cholinergic syndrome

C. Wermuth, P. Soubrié, R. Boigegrain, 1992 .

Lead Identification for Modulators of Multidrug Resistance based on in silico Screening with a Pharmacophoric Feature Model

G. Ecker, T. Langer, R. Hoffmann, 2004, Archiv der Pharmazie.

Discovery of high-affinity ligands of sigma1 receptor, ERG2, and emopamil binding protein by pharmacophore modeling and virtual screening.

Thierry Langer, Christian Laggner, Rémy D Hoffmann, 2005, Journal of medicinal chemistry.

Discovery of high-affinity ligands of σ1 receptor, ERG2, and emopamil binding protein by pharmacophore modeling and virtual screening

Thierry Langer, Rémy D. Hoffmann, Christian Laggner, 2005 .

High-Potency Olfactory Receptor Agonists Discovered by Virtual High-Throughput Screening: Molecular Probes for Receptor Structure and Olfactory Function

E. V. Name, J. Ngai, N. Triballeau, 2008, Neuron.

Chemical function based pharmacophore models as suitable filters for virtual 3D-database screening

Thierry Langer, Rémy D. Hoffmann, T. Langer, 2000 .

Structure-based virtual screening: an application to human topoisomerase II alpha.

H. Bertrand, R. Hoffmann, A. Goupil-Lamy, 2004, Journal of medicinal chemistry.

On the Use of Chemical Function-Based Alignments as Input for 3D-QSAR

Thierry Langer, Rémy D. Hoffmann, T. Langer, 1998, J. Chem. Inf. Comput. Sci..

Chemical Function Based Alignment Generation for 3D QSAR of Highly Flexible Platelet Aggregation Inhibitors

T. Langer, R. Hoffmann, P. Lukavsky, 2000 .

5-HT3 antagonists derived from aminopyridazine-type muscarinic M1 agonists.

C. Wermuth, Y. Rival, J. Bourguignon, 1998, Journal of medicinal chemistry.

Conformation-activity relationship study of 5-HT3 receptor antagonists and a definition of a model for this receptor site.

R. Hoffmann, R. Miller, M. Hibert, 1990, Journal of medicinal chemistry.

Structure and molecular modeling of GABAA receptor antagonists.

D. Rognan, C. Wermuth, R. Hoffmann, 1992, Journal of medicinal chemistry.

A 3D QSAR Study of Monoamino Oxidase-B Inhibitors Using the Chemical Function Based Pharmacophore Generation Approach

R. Hoffmann, S. Guccione, G. Raciti, 2001, Journal of enzyme inhibition.

Pharmacophore Model Generation Software Tools

Rémy D. Hoffmann, Konstantin Poptodorov, Tien Luu, 2006 .

Pharmacophore modelling: applications in drug discovery

Thierry Langer, Rémy D Hoffmann, T. Langer, 2006, Expert opinion on drug discovery.

Hit finding: towards 'smarter' approaches.

Thierry Langer, Sharon Bryant, Rémy Hoffmann, 2009, Current opinion in pharmacology.

Parallel Screening and Activity Profiling with HIV Protease Inhibitor Pharmacophore Models

Thierry Langer, Rémy D. Hoffmann, Daniela Schuster, 2007, J. Chem. Inf. Model..

Structure-Based Virtual Screening: An Application to Human Topoisomerase II α

Rémy D. Hoffmann, Serge Fermandjian, Hugues-Olivier Bertrand, 2004 .

Pharmacophores and Pharmacophore Searches: LANGER: PHARMACOPHORES AND PHARMACOPHORE SEARCHES O-BK

Thierry Langer, Rémy D. Hoffmann, T. Langer, 2006 .

CATALYST Pharmacophore Models and Their Utility As Queries for Searching 3D Databases

Peter W. Sprague, Remy Hoffmann, P. Sprague, 2007 .

Virtual screening: an effective tool for lead structure discovery?

T. Langer, R. Hoffmann, R. D. Hoffmann, 2001, Current pharmaceutical design.